Full Press Release Details
Provides Update Following Class Action Dismissal
The Tel Aviv-Yafo District Court ruled in favor of InterCure and the defendants, dismissing the suit and ordering plaintiffs to
YORK and HERZLIYA, Israel - May 21, 2024 - InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure"
or the "Company"), the leading cannabis company outside of North America, today announced that, further to the Company's
press release issued on April 25, 2023, in which the Company reported that, on April 23, 2023, it has informed that an application for
approval of a class action in Israel was filed against twenty-six defendants, among them the leading cannabis groups in Israel, including
the Company and three of its subsidiaries in which the subject of the application is the alleged claim that the defendants are in violation
of the advertising prohibitions included in the Israeli regulations overseeing medical cannabis in Israel, the Company hereby reports
that on May 16, 2024, the Tel Aviv-Yafo District Court issued a judgment dismissing the personal claims of each plaintiff and the said
class action lawsuit against the defendants, ordering the plaintiffs to pay the defendants's legal expenses.
InterCure (dba Canndoc):
(dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America.
Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good
Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution
network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the
fastest growing cannabis global market outside of North America.
more information, visit: www.intercure.co.
Amos Cohen, Chief Financial Officer